MiNK Therapeutics, Inc. INKT 深 沪
等待开盘 05-22 09:30:00 美东时间
10.94
+0.220
+2.05%
华盛通- 最 高11.00
- 今 开10.62
- 成交量 1.54万股
- 最 低 10.4101
- 昨 收 10.72
- 总市值 5450.20万
- 52周最高 76.00
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 6.80
- 委 比 -87.04%
- 总股本 498.19万
- 历史最高 221.55
- 量 比 0.35
- 振 幅 5.50%
- 历史最低 4.632
- 每 手 1
- 风险率 4.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MiNK Therapeutics Presents New Clinical, Translational Data On Agent-797 Showing Pathogen Suppression, Lung Immune Restoration And Tissue Repair Activation, Supporting Ongoing Phase 2 Trial, At ATS 2026
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases
05-20 23:10
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call
MiNK Therapeutics (NASDAQ:INKT) held its first-quarter earnings conference call...
05-15 21:46
MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from
05-15 19:36
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
MiNK Therapeutics Presents Data Showing Agent-797, Off-The-Shelf, Allogeneic iNKT Cell Therapy Produces Fundamentally Different, Disease-Appropriate Immune Responses At ASGCT 2026
iNKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — from the same manufacturing donor batch, without genetic engineeringFindings
05-12 19:39
MiNK Therapeutics Presents Data From Investigator-Initiated Phase II Trial, Evaluating agenT-797, MiNK's allo-iNKT Cell Therapy, In Combination With BOT And BAL, Ramucirumab And Paclitaxel In PD-1 Refractory Gastroesophageal Cancer, At 2026 AACR Annual Meeting
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patientsInduction
04-18 03:03
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
